881 results on '"Costa, Daniel B."'
Search Results
152. Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection
153. Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?
154. Successive Sub-Array Activation for Massive MIMO-NOMA Networks
155. Error Probability of $ M$-Phase Signaling With Phase Noise Over Fading Channels
156. Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
157. Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
158. Achievable Sum Rate and Outage Capacity of GFDM Systems with MMSE Receivers
159. Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
160. Performance Analysis of Wireless Communication Systems Subject to κ-μ Extreme Fading
161. Association of extended dosing intervals or delays in pembrolizumab-based regimens with survival outcomes in advanced non-small cell lung cancer
162. In search of goldilocks: the quest to optimize combination drug strategies for the management of advanced stage non-small-cell lung cancer
163. Analysis and Optimization of Tail-Biting Spatially Coupled Protograph LDPC Codes for BICM-ID Systems
164. Impact of Hardware Impairments on Cognitive Satellite-Terrestrial Relaying with a Direct Link
165. Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related Dermatitis
166. Performance Analysis of Downlink NOMA Systems Over $\kappa$-$\mu$ Shadowed Fading Channels
167. Impact of Wireless-Powered Communications in Coexisting Mobile Networks
168. Serum Concentrations of Erlotinib at a Dose of 25 mg Daily
169. EGFR-mutated lung cancers resistant to osimertinib through EGFR-C797S respond to 1(st) generation reversible EGFR inhibitors but eventually acquire EGFR-T790M/C797S in preclinical models and clinical samples
170. Erlotinib-Associated Alopecia in a Lung Cancer Patient
171. Improvement of Type 2 Diabetes in a Lung Cancer Patient Treated With Erlotinib
172. A novel mutation in the last exon of ATRX in a patient with α-thalassemia myelodysplastic syndrome
173. Recurrent Infections in Multiple Myeloma
174. Hyperglycemia and biliary tract adenocarcinoma
175. Modern Treatment of Lung Cancer: CASE 3. Non-Metastatic Bilateral F-18 Fluorodeoxyglucose Avid Adrenal Glands in Non–Small-Cell Lung Cancer
176. DIABETES MELLITUS AS THE PRESENTING FEATURE OF EXTRAHEPATIC CHOLANGIOCARCINOMA IN SITU: CASE REPORT AND REVIEW OF LITERATURE
177. Interference Analysis for Secondary Coexistence in Licensed Networks
178. TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
179. From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer
180. Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?
181. Antitumor activity of TAK-788 in NSCLC With EGFR exon 20 insertions
182. Error Probability of alpha-µ Fading Channels with Imperfect Carrier Phase Recovery
183. Cascaded Fluctuating Two-Ray Fading Channels
184. Non-Linear Energy Harvesting Based Cooperative Spectrum Sharing Networks
185. GFDM-Based Cooperative Relaying Networks with Wireless Energy Harvesting
186. Performance analysis of dual-hop AF relaying over α-μ fading channels
187. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis
188. Abstract 320: Met/Ror1-β-catenin-Bcl-xL axis contributes to the emergence of drug-tolerant cells that evolve into resistant tumors inEGFR-mutant lung cancer
189. Abstract 1329: Preclinical evaluation of TAS6417 as a highly effective, pan-mutation-selective EGFR tyrosine kinase inhibitor
190. On the Performance of $\alpha$ –$\eta$ –$\kappa$ –$\mu$ Fading Channels
191. Novel Results for the Multivariate Ricean Distribution With Non-Identical Parameters
192. Cooperative Relaying with Energy Harvesting: Performance Analysis Using Extreme Value Theory
193. Secrecy Analysis of a TAS/MRC Scheme in $\alpha-\mu$ Fading Channels
194. Sequential Relay Selection in D2D-Enabled Cellular Networks With Outdated CSI Over Mixed Fading Channels
195. SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
196. Performance Analysis of Digital Communication Systems Over $\alpha$ -$\kappa$ -$\mu$ Fading Channels
197. Physical Layer Security Over$\alpha$ - $\kappa$ - $\mu$and$\alpha$ - $\eta$ - $\mu$Fading Channels
198. Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer
199. Effective Channel Blind Estimation in Cell-Free Massive MIMO Networks
200. Ascending role of next-generation ALK inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.